Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573222 | 0.85 | MAPT (0.76) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3807661 | 0.84 | MAPT (0.64) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1136833 | 0.84 | MAPT (0.64) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL27980498 | 0.83 | SMN1; SMN2 (0.68) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL20306312 | 0.83 | MAPT (0.62) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2471189 | 0.83 | MAPT (0.62) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1019005 | 0.83 | MAPT (0.62) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13278634 | 0.82 | MAPT (0.56) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL27966395 | 0.82 | GPR119 (0.71) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL29707320 | 0.82 | MAPT (0.50) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | VALO HEALTH, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| CN-112823037-B | Inhibition of deubiquitinase USP25 and USP28 | 瓦洛健康股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3833441-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112823037-A | Inhibition of deubiquitinase USP25 and USP28 | 瓦洛早期发现股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| WO-2020033709-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033709-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | USP28, USP25, USP30 | GPR119 3774/4885MAPT 3174/4885LMNA 3920/4885 |
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | USP28, USP25, USP30 | GPR119 3774/4885MAPT 3174/4885LMNA 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.